Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study Protocol AN4005X0101 An Open-Label, Multicenter, Phase 1 Study of AN4005 in Patients With Advanced Tumors

NCT04999384 is registered in ClinicalTrials.gov with Adlai Nortye Biopharma Co., Ltd. as lead sponsor.

NCT NCT04999384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04999384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study Protocol AN4005X0101 An Open-Label, Multicenter, Phase 1 Study of AN4005 in Patients With Advanced Tumors
Lead sponsor
Adlai Nortye Biopharma Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
September 27, 2021
Completion date
December 31, 2026
Enrollment
31 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced lymphoma, advanced solid tumor